Hospital Kuala Lumpur, Jalan Pahang, Malaysia.
Novartis Corporation (M) Sdn Bhd, Petaling Jaya, Selangor, Malaysia.
J ASEAN Fed Endocr Soc. 2023;38(1):75-80. doi: 10.15605/jafes.038.01.06. Epub 2023 Feb 2.
This study aims to report the demographic features of patients with acromegaly, the disease burden, and the corresponding treatment patterns and outcomes in Malaysia.
This is a retrospective study that included patients from the Malaysian Acromegaly registry who were diagnosed with acromegaly from 1970 onwards. Data collected included patient demographics, clinical manifestations of acromegaly, biochemical results and imaging findings. Information regarding treatment modalities and their outcomes was also obtained.
Registry data was collected from 2013 to 2016 and included 140 patients with acromegaly from 12 participating hospitals. Median disease duration was 5.5 years (range 1.0 - 41.0 years). Most patients had macroadenoma (67%), while 15% were diagnosed with microadenoma. Hypertension (49.3%), diabetes (37.1%) and hypopituitarism (27.9%) were the most common co-morbidities for patients with acromegaly. Majority of patients had surgical intervention as primary treatment (65.9%) while 20.7% were treated medically, mainly with dopamine agonists (18.5%). Most patients had inadequate disease control after first-line treatment regardless of treatment modality (79.4%).
This registry study provides epidemiological data on patients with acromegaly in Malaysia and serves as an initial step for further population-based studies.
本研究旨在报告马来西亚肢端肥大症患者的人口统计学特征、疾病负担以及相应的治疗模式和结局。
这是一项回顾性研究,纳入了自 1970 年以来在马来西亚肢端肥大症登记处确诊为肢端肥大症的患者。收集的数据包括患者的人口统计学特征、肢端肥大症的临床表现、生化结果和影像学发现。还获得了有关治疗方式及其结局的信息。
登记处的数据收集于 2013 年至 2016 年,包括来自 12 家参与医院的 140 例肢端肥大症患者。中位疾病病程为 5.5 年(范围 1.0-41.0 年)。大多数患者有大腺瘤(67%),而 15%被诊断为微腺瘤。肢端肥大症患者最常见的合并症为高血压(49.3%)、糖尿病(37.1%)和垂体功能减退症(27.9%)。大多数患者接受了手术干预作为一线治疗(65.9%),而 20.7%接受了药物治疗,主要是多巴胺激动剂(18.5%)。无论治疗方式如何,大多数患者在一线治疗后疾病控制不足(79.4%)。
本登记研究提供了马来西亚肢端肥大症患者的流行病学数据,是进一步进行基于人群的研究的初步步骤。